This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
=== Acute gastroenteritis === A position paper from the ESPGHAN Working Group for Probiotics and Prebiotics, based on systematic reviews and randomized controlled trials, suggested that S. boulardii may be considered as an adjunct to rehydration therapy in the management of acute gastroenteritis in children. The recommendation was classified as strong despite the underlying evidence being rated as low quality.
== Bibliography == Elyse; Houde, Alain (2002). "La PCR en temps réel: principes et applications" (PDF). Reviews in Biology and Biotechnology. 2 (2): 2–11. Archived from the original (PDF) on 2009-06-12. Bustin, SA (2000). "Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays". J Mol Endocrinol. 25 (2): 169–193. doi:10.1677/jme.0.0250169. PMID 11013345. Higuchi, R.; Dollinger, G.; Walsh, P.S.; Griffith, R. (1992). "Simultaneous amplification and detection of specific DNA-sequences". Bio-Technology. 10 (4): 413–417. doi:10.1038/nbt0492-413. PMID 1368485. S2CID 1684150. Holland, P.M.; Abramson, R.D.; Watson, R.; Gelfand, D.H. (1991). "Detection of specific polymerase chain reaction product by utilizing the 50 !30 exonuclease activity of Thermus aquaticus DNA polymerase". Proc. Natl. Acad. Sci. USA. 88 (16): 7276–7280. Bibcode:1991PNAS...88.7276H. doi:10.1073/pnas.88.16.7276. JSTOR 2357665. PMC 52277. PMID 1871133. Kubista, M; Andrade, JM; Bengtsson, M; Forootan, A; Jonak, J; Lind, K; Sindelka, R; Sjoback, R; Sjogreen, B; Strombom, L; Stahlberg, A; Zoric, N (2006). "The real-time polymerase chain reaction". Mol. Aspects Med. 27 (2–3): 95–125. doi:10.1016/j.mam.2005.12.007. PMID 16460794. Higuchi, R.; Fockler, C.; Dollinger, G.; Watson, R. (1993). "Kinetic PCR: Real time monitoring of DNA amplification reactions". Biotechnology. 11 (9): 1026–1030. doi:10.1038/nbt0993-1026. PMID 7764001. S2CID 5714001. Filion, M. (2012). Quantitative Real-time PCR in Applied Microbiology. Caister Academic Press. ISBN 978-1-908230-01-0.
A lower-end product includes salt, hydrogenated fat, monosodium glutamate, flavor enhancers, and flavors. It is labelled as "beef flavor" without beef. A mid-end product typically combines cheaper sources of flavor with actual meat/bone/vegetable (usually first cooked into an extract) and/or animal fat. For example, Maggi bouillon cubes are manufactured from iodized salt, hydrogenated palm oil, wheat flour, flavor enhancers (monosodium glutamate, disodium inosinate, disodium guanylate), chicken fat, chicken meat, sugar, caramel, yeast extract, onion, spices (turmeric, white pepper, coriander), and parsley. A high-end product typically mainly rely on meat/bone/vegetable (usually extracted) for the meaty flavor and savoriness, such as described in a 2004 patent. As an example, "Better than Bouillion" is made from roasted chicken, salt, sugar, maltodextrin, chicken stock, yeast extract, onion powder, garlic powder, tumeric, and flavoring.
The RTG was invented in 1954 by Mound Laboratories scientists Kenneth (Ken) C. Jordan (1921–2008) and John Birden (1918–2011). They were inducted into the National Inventors Hall of Fame in 2013. Jordan and Birden worked on an Army Signal Corps contract (R-65-8- 998 11-SC-03-91) beginning on 1 January 1957, to conduct research on radioactive materials and thermocouples suitable for the direct conversion of heat to electrical energy using polonium-210 as the heat source. RTGs were developed in the US during the late 1950s by Mound Laboratories in Miamisburg, Ohio, under contract with the United States Atomic Energy Commission. The project was led by Dr. Bertram C. Blanke. The first RTG launched into space by the United States was SNAP 3B in 1961 powered by 96 grams of plutonium-238 metal, aboard the Navy Transit 4A spacecraft. One of the first terrestrial uses of RTGs was in 1966 by the US Navy at uninhabited Fairway Rock in Alaska. RTGs were used at that site until 1995. A common RTG application is spacecraft power supply. Several generations of RTG design have been used for probes that traveled far from the Sun, rendering solar panels impractical. As such, they have been used for Pioneer 10 and 11; Voyager 1 and 2; Galileo; Ulysses; Cassini; New Horizons; and are planned for the Dragonfly mission to Titan. RTGs were also used instead of solar panels to power the two Viking landers, and for the scientific experiments left on the Moon by the crews of Apollo 12 through 17 (SNAP 27s).
=== Metalorganic addition === Interaction of ethylene oxide with organomagnesium compounds, which are Grignard reagents, can be regarded as nucleophilic substitution influenced by carbanion organometallic compounds. The final product of the reaction is a primary alcohol:
Sources: en.wikipedia.org
Peter Benenson (born Peter James Henry Solomon; 31 July 1921 – 25 February 2005) British lawyer, writer, pamphleteer, human rights activist and the founder of human rights group Amnesty International (AI); accepted the Pride of Britain Award for Lifetime Achievement in 2001 though he later rejected and denounced Amnesty International for its criticism of Israel. Benenson was the son of British-born Harold Solomon and Russian-born Flora Benenson, grandson of Russian financier Grigori Benenson (1860–1939); served in Intelligence Corps at the Ministry of Information and worked at Bletchley Park during World War II as a cryptographer. Leila Berg (12 November 1917 – 17 April 2012) was an English children's author, editor and play specialist. She was well known as a journalist and a writer on education and children's rights. Berg was a recipient of the Eleanor Farjeon Award. John Berger, Jewish father, convert to Roman Catholicism, (5 November 1926 – 2 January 2017) English art critic, novelist, painter and poet. Berger's essay on art criticism Ways of Seeing, is known as a foundation text employing deconstruction and feminist prisms of epistemology and ontology, questioning axiomatic assumptions about gender, racial prejudice and Orientalism, whilst introducing and debating prisms of Psychological projection, Reification (Marxism), False Consciousness, Commodity fetishism, Marx's theory of alienation and essentialism. He was a supporter of the Palestinian cause, and, focused on Israel and apartheid, a member of the Support Committee of the Russell Tribunal on Palestine.
GGT is a microsomal enzyme found in hepatocytes, biliary epithelial cells, renal tubules, pancreas, and intestines. It helps in glutathione metabolism by transporting peptides across the cell membrane. Much like ALP, GGT measurements are usually elevated if cholestasis is present. In acute viral hepatitis, the GGT levels can peak at 2nd and 3rd week of illness, and remained elevated at 6 weeks of illness. GGT is also elevated in 30% of the hepatitis C patients. GGT can increase by 10 times in alcoholism. GGT can increase by 2 to 3 times in 50% of the patients with non-alcoholic liver disease. When GGT levels are elevated, the triglyceride level is elevated also. With insulin treatment, the GGT level can reduce. Other causes of elevated GGT are: diabetes mellitus, acute pancreatitis, myocardial infarction, anorexia nervosa, Guillain–Barré syndrome, hyperthyroidism, obesity and myotonic dystrophy. In pregnancy conditions GGT activity is reduced in 2nd and 3rd trimesters. In hyperemesis gravidarum, GGT level value can reach 45 IU/L, 17 IU/L in pre-eclampsia, and 35 IU/L in HELPP syndrome.
== Historical context == In 1992, Stephen Kent and Martina Schnölzer at The Scripps Research Institute developed the "Chemical Ligation" concept, the first practical method to covalently condense unprotected peptide segments; the key feature of chemical ligation is formation of an unnatural bond at the ligation site. Just two years later in 1994, Philip Dawson, Tom Muir and Stephen Kent reported "Native Chemical Ligation", an extension of the chemical ligation concept to the formation of a native amide ('peptide') bond after initial nucleophilic condensation formed a thioester-linked condensation product designed to spontaneously rearrange to the native amide bond at the ligation site. Theodor Wieland and coworkers had reported the S-to-N acyl shift as early as 1953, when the reaction of valine-thioester and cysteine amino acid in aqueous buffer was shown to yield the dipeptide valine-cysteine. The reaction proceeded through the intermediacy of a thioester containing the sulfur of the cysteine residue. However, Wieland's work did NOT lead to the development of the native chemical ligation reaction. Rather, the study of amino acid thioester reactions led Wieland and others to develop the 'active ester' method for the synthesis of protected peptide segments by conventional chemical methods carried out in organic solvents.
== Characteristics == Elastin is a very long-lived protein, with a half-life of over 78 years in humans. However, its long lifespan does not imply that its functional properties remain unchanged throughout life. In human skin, ageing is associated with changes in the amount, organisation and integrity of dermal elastic fibres. An in vivo multiphoton tomography study reported age-related reductions in the measured elastin and collagen content of the human dermis. More recent three-dimensional imaging of human dermal elastin has shown that the number of elastic fibres decreases with age and that the remaining network becomes more fragmented and less interconnected. Finite-element modelling based on these structural observations associated age-related changes in elastin-fibre architecture with reduced skin firmness.
Sources: en.wikipedia.org
The figures echoed similar findings from unpublished data on 3.8 million Russians, according to which Sputnik V demonstrated an efficacy of 97.7%. A study published by the Journal of Medical Internet Research analysed the dataset consisted of 11,515 self-reported Sputnik V vaccine adverse events posted on Telegram. Telegram users complained mostly about pain, fever, fatigue, and headache.
== Biological importance == Aside from the necessity of wobble, that our cells have a limited amount of tRNAs and wobble allows for more flexibility, wobble base pairs have been shown to facilitate many biological functions, most clearly demonstrated in the bacterium Escherichia coli, a model organism. In fact, in a study of E. coli's tRNA for alanine there is a wobble base pair that determines whether the tRNA will be aminoacylated. When a tRNA reaches an aminoacyl tRNA synthetase, the job of the synthetase is to join the t-shaped RNA with its amino acid. These aminoacylated tRNAs go on to the translation of an mRNA transcript, and are the fundamental elements that connect to the codon of the amino acid. The necessity of the wobble base pair is illustrated through experimentation where the Guanine-Uracil pairing is changed to its natural Guanine-Cytosine pairing. Oligoribonucleotides were synthesized on a Gene Assembler Plus, and then spread across a DNA sequence known to code a tRNA for alanine, 2D-NMRs are then run on the products of these new tRNAs and compared to the wobble tRNAs. The results indicate that with that wobble base pair changed, structure is also changed and an alpha helix can no longer be formed. The alpha helix was the recognizable structure for the aminoacyl tRNA synthetase and thus the synthetase does not connect the amino acid alanine with the tRNA for alanine. This wobble base pairing is essential for the use of the amino acid alanine in E. coli and its significance here would imply significance in many related species.
in the manufacturing processes involved with an aircraft of this size, including titanium structures, chemical milling and the machining of integral panels." By the mid-1980s, PZL was planned to produce half of the Il-86, including the entire wing, and also to work on Il-86 developments (“Now we are preparing to manufacture units for the next model of the Il wide-body plane,” according to Belczak). From May 1977, the Polish factory manufactured entire empennages including tailplanes and the fin, all control surfaces, high-lift devices and engine pylons for the Il-86, representing "about 16 per cent of these aircraft." Amid labour and political unrest in Poland from 1980 onwards, the Voronezh factory was instructed to retain wing manufacture. After certification in 1980, annual Il-86 outputs were: 1980, 1; 1981, 0; 1982, 11; 1983, 12; 1984, 8; 1985, 9 (including the four for 8 ADON); 1986, 11; 1987, 10; 1988, 10; 1989, 9; 1990, 11 (including the three for export to China), 1991, 3. Of the 106 examples built, one never flew (being used for static tests) and three were exported. The five-year plan in force when the USSR ceased to exist called for 40 more aircraft to be manufactured by 1995, but the manufacturing facility closed in early 1992.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.